RESEARKA

Within the corpus, tensions in the longevity outcome class arise primarily from differences in effect certainty and directness. By contrast, the Agarwal 2025 polypill protocol represents a future interventional approach but does not yet report a definitive null or positive effect on longevity, reflecting an anticipated rather than an observed outcome (Agarwal 2025). In contrast, the observational cohort by Murray-Thomas 2025 demonstrates a clear, statistically significant negative consequence of ARB non-adherence on mortality (Murray-Thomas 2025). The Jin 2025 cohort study on guideline-directed therapy in acute coronary syndrome patients with renal dysfunction provides corroborating observational evidence for the importance of therapy adherence, aligning with Murray-Thomas 2025 in highlighting the role of medication use in survival, though specific effect sizes for ARBs remain unclear (Jin 2025). The Wang 2026 meta-analysis adds a layer of complexity by situating ARBs within a multi-therapy landscape where newer agents like SGLT2i show strong mortality benefits, potentially challenging the incremental longevity value of ARBs alone (Wang 2026).

Citation Support

• source_1 Solomon 2026
• source_2 Din 2026
• source_3 Li 2025
• source_4 Mei 2025
• source_5 Chung 2024